Can-Fite BioPharma Ltd.
CANF
$3.39
$0.030.89%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -39.91% | -25.77% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -39.91% | -25.77% | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -39.91% | -25.77% | -- | -- | -- |
| SG&A Expenses | 20.18% | 20.51% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.62% | 15.45% | -- | -- | -- |
| Operating Income | -22.39% | -18.83% | -- | -- | -- |
| Income Before Tax | -24.72% | -23.02% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.72% | -23.02% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.72% | -23.02% | -- | -- | -- |
| EBIT | -22.39% | -18.83% | -- | -- | -- |
| EBITDA | -22.20% | -18.61% | -- | -- | -- |
| EPS Basic | 41.04% | 36.29% | -- | -- | -- |
| Normalized Basic EPS | 40.97% | 36.44% | -- | -- | -- |
| EPS Diluted | 41.04% | 36.29% | -- | -- | -- |
| Normalized Diluted EPS | 40.97% | 36.44% | -- | -- | -- |
| Average Basic Shares Outstanding | 126.97% | 106.61% | -- | -- | -- |
| Average Diluted Shares Outstanding | 126.97% | 106.61% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |